.png){kind=icon}
.png){kind=icon}
Return
Intelligent Monitoring of Biosynthesized HMOs: Universal Viable Bacteria and DNA Detection Technologies
.png){kind=icon}
PRE
AI
T
Y
P
程
DOI：10.1016/j.trac.2026.119047.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Residual viable microorganisms and exogenous DNA represent key biosafety concerns in HMO biomanufacturing. • Complex fermentation matrices remain a major obstacle to rapid and reliable on-site analysis. • Emerging biosensors are transforming viable-cell detection beyond traditional culture-based approaches. • Programmable nuclease technologies, including CRISPR/Cas and Argonaute, improve the accuracy of residual DNA monitoring. • The convergence of biosensing, POCT, and artificial intelligence is enabling intelligent and traceable quality control for HMOs.
Journal
IF:
12
Papers:
7.2K
Citations:
3.9W
Organization
Cited Papers